MEDIFAST, INC. (MED)
Consumer Defensive › Miscellaneous Food Preparations & Kindred Products
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 119% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 0.3% — below-average profitability
- Revenue declining 36% annually
MEDIFAST, INC. (MED) is a Consumer Defensive company operating in Miscellaneous Food Preparations & Kindred Products, listed on the NYSE , with a market capitalisation of $111 million . Key value metrics: P/E ratio 192.7, P/B ratio 0.56, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
MEDIFAST, INC. — Fundamental Analysis Summary
MEDIFAST, INC. (MED) is currently trading 119% above its Graham Number of $4.62, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 192.7x.
On financial health, MED shows a moderate Piotroski F-Score of 4/9, and modest return on equity of 0.3% (sector average: 6.7%), and minimal leverage with a debt-to-equity ratio of 0.25.
StockPik's composite Value Score for MED is 70/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
MED reports a high gross margin of 72.9% (sector average: 25.1%) and a negative operating margin of -1.0%.
MED shows revenue declining at 36% year-over-year, with earnings declining at 993%.